Skip to main content
. 2016 Aug 3;7(35):57171–57185. doi: 10.18632/oncotarget.11036

Figure 5. Selumetinib enhances the anti-migratory effects of LDN-193189 in MPNST cells.

Figure 5

A. and B. Representative images of the analyzed cellular wound area of low passage ST88-14 (Nf1−/−) and T265 (Nf1−/−) cells taken at different time points during the course of the migration assay. Cells were infected with lentiviral GFP to allow for quantification of images. The pre-treatment images were taken upon creation of the wound field and cell migration into the wound field was followed for the next 24-48 hours post-treatment. C. The percent quantification of the wound area analyzed using ImageJ was normalized to the pre-treatment wound area for each condition. LDN-193189 (0.003 μM) significantly reduces the motility in both cell lines as compared to the control (P<0.0001), however treatment with selumetinib alone does not affect motility. Combinatorial treatment significantly decreases MPNST cellular migration in LP ST88-14 (Nf1−/−), whereas the combination treatment effect is insignificant in the LP T265 (Nf1−/−) cells, as compared to treatment with LDN-193189 alone. BI values represent a weakly synergistic to an additive effect of drug combination on motility. Data presented are the average of quantification of the wound areas of at least three independent experiments ± S.D (n=3, Two-way ANOVA for comparing each time point and condition with another, followed by Bonferroni's test for multiple comparisons).